The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
Preclinical evidence supports the investigation of histone deacetylase inhibitors for the treatment of myeloma. Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored.
Prince
H Miles
HM
Haematology Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Bishton
Mark
M
Harrison
Simon
S
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D007211:Indoles; D009101:Multiple Myeloma / Q000188:drug therapy*; D000077767:Panobinostat; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D000077767:Panobinostat; C502418:givinostat hydrochloride